This treatment is administered to patients with metastatic prostate tumours who do not respond adequately to standard treatment protocols and/or have clinical and biochemical progression. The treatment is not applied in renal failure, severe hepatic failure, severe heart failure. Ga-68 PSMA PET/CT imaging is performed before treatment to evaluate the extent of disease and areas of involvement. If there is involvement on imaging and if complete blood count, liver and kidney function tests are within the appropriate range for treatment, treatment is planned. For each patient, 4 treatment doses are planned with 4-6 week intervals. Your treatment is administered by slow intravenous injection of the radiopharmaceutical. Very rarely, there may be temporary side effects such as mild nausea following the injection. After treatment On the 1st day, your whole body scan is performed. Since kidney dysfunction and bone marrow suppression may develop due to treatment, complete blood count and kidney function tests should be performed at the 3rd week after treatment.